COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Therapeutic Option for Hepatitis B and C: a French Cohort (HEPATHER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01953458
Recruitment Status : Recruiting
First Posted : October 1, 2013
Last Update Posted : October 5, 2017
Bristol-Myers Squibb
Gilead Sciences
Janssen-Cilag Ltd.
Merck Sharp & Dohme Corp.
Roche Pharma AG
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : August 2022
Publications automatically indexed to this study by Identifier (NCT Number):